For example, in basal cell carcinoma, nuclear localisation of SMO via a nuclear/nucleolar localisation signal activates GLI1 independently of canonical SMO inhibitors, explaining resistance in ~80% of patients [54]. The gene discussed is GLI1; the disease is basal cell carcinoma.